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Abstract INTRODUCTION: The number of cytotoxic immune cells grows in the endometrium 
during the secretory cycle phase. RCAS1 is a protein inhibiting the activated immune 
cytotoxic cells. The expression of RCAS1 has been confirmed in endometrium. The 
aim of the present study was to evaluate the RCAS1 expression alterations with 
respect to the menstrual cycle changes and the number and activity of cytotoxic 
immune cells. 
MATERIAL AND METHODS: RCAS1, CD25, CD69, CD56, CD16, CD68 antigens 
expression was assessed by immunohistochemistry in endometrial tissue samples 
which were obtained from 33 patients. Tissue samples were classified according to 
the menstrual cycle phases, with division of the cycle into three phases: proliferative 
(8 cases), periovulatory (10 cases), and secretory (15 cases) ones.
RESULTS: A significantly higher RCAS1 expression was observed in the periovula-
tory and the secretory menstrual cycle phases than in the proliferative phase. The 
changes in RCAS1 expression were combined with significant differences in the 
number of immune cells and their activity. The highest level of CD69 antigen 
expression was observed during the periovulatory cycle phase, while the highest 
level of CD25 antigen expression was observed during proliferative phase, the 
number of CD56 positive cells was at the highest level during the secretory cycle 
phase. No significant differences in the number of macrophages and CD16 antigen 
expression were observed with respect to the menstrual cycle phases. 
CONCLUSION: RCAS1 endometrial expression may favor the coexistence of active 
lymphocytes and endometrial cells.
 
Introduction
The endometrium with decidual changes is a 
phenomenon playing a crucial role in reproduction. 
During decidualization the number of immune 
cells grows and the endometrium is ready for 
the ovum implantation (implantation window). 
Epithelial endometrial cells are surrounded then 
by a high number of mononuclear cells including 
NK, macrophages, T lymphocytes and other cells 
[7,18,25,33,34,37]. The presence of immune cells 
is necessary for the ovum implantation and further 
development of pregnancy. Many chemokines 
and particles appearing in the endometrium at 
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the time of the implantation window are typified by 
immunomodulating activity. They include: interleukins 
(IL-1, Il-15, IL13, IL-2), Galectin-9, LIF (Leukemia 
inhibitory factor), RANTES (mRNA transcripts encod-
ing regulated on activation, normal T-cell-expressed and 
-secreted), CAP, metalothionein, Fas-L, prolactin   and 
others [2,11,13,16,20,21,27,28,33,40,41,50]. Recently, the 
alterations in RCAS1 (Receptor associated cancer antigen 
presenting on SiSo cells) expression within the reproduc-
tive tract epithelium including the fallopian tube, and the 
endometrium were reported [17,44].
 RCAS1 is a protein responsible for tumor escape from 
the host immunological surveillance [5,26,30,38,39] but 
its expression was also demonstrated in many physiologi-
cal conditions participating in the regulation of cytotoxic 
cells activity. It was also described in the bone marrow, 
palatine tonsils and the placenta [1,8,24,29,43,45,46]. 
Similarly RCAS1 expression has been disclosed in 
immune mediated diseases including endometriosis, 
nasal polyps and liver diseases [8,10,48]. It was therefore 
concluded that RCAS1 expression in the healthy repro-
ductive tract epithelium might be associated with the 
effect on immune cytotoxic activity [44]. 
The aim of the present study was to evaluate RCAS1 
expression alterations with respect to the immune cells 
identification and activity through the assessment of such 
antigens as CD56, CD68, CD16, CD25, CD69 and with 
respect to the menstrual cycle phases, i.e. proliferative, 
periovulatory and secretory ones. 
Material and Methods
Human subject
Eutopic human endometrium tissues were obtained 
from 33 non-menopausal fertile women, aged 30–47 
years. These patients underwent hysterectomy because 
of a benign gynecological indication (leiomyomas). No 
patient included in our study received any hormonal 
treatment. The surgical procedure was performed in the 
Gynecology and Infertility Department of the Jagiel-
lonian University in Krakow, Poland. All tissue samples 
were verified by the standard histology method using 
the hematoxylin and eosin staining technique follow-
ing a formalin fixation. Tissue samples were classified 
according to the menstrual cycle phases, with division 
of the cycle into three phases: proliferative (8 cases), 
periovulatory (10 cases), and secretory (15 cases) ones. 
The endometrial samples from uterine corpus included 
the entire thickness of the endometrium (basal and 
superficial part, composed of stromal cells and glandular 
epithelial cells). 
Patients’ consent was obtained in all cases. The 
approval of the research program by the Jagiellonian 
University Ethical Committee was obtained prior to the 
study (KBET/89/B/2005).
Immunohistochemistry
Immunohistochemical analysis was performed in 
the Pathology Department of the Jagiellonian University. 
Five-micrometer slides from each case, encompassing 
the endometrium, prepared routinely for immunohis-
tochemistry, were stained to visualize the expression of 
RCAS1 and CD16, CD56, CD69, CD25, CD56-positive 
cells (mainly lymphocytes) as well as CD68+ cells, that is 
macrophages. 
In all cases immunohistochemistry was performed 
applying the Envision method using Dako Autostainer. 
For RCAS1 immunostaining the slides were treated with 
the mouse monoclonal antibody Anti-RCAS1 (Medical 
and Biological Laboratories, Naka-ku Nagoya, Japan in 
DAKO Antibody Diluent with Background Reducing 
Components-DAKO, Denmark, dilution 1:1000) in 
the moist chamber overnight. To immunolocalize the 
immune infiltrate cells the monoclonal antibodies were 
applied: CD56 (NCAM; NCL-CD56-504, Novocastra) in 
dilution 1:100, CD69 (NCL-CD69, Novocastra) in dilu-
tion 1:25, CD25 (Interleukin-2 Receptor, NCL-CD25-
305, Novocastra) in dilution 1:25, CD16 (NCL-CD16, 
Novocastra) in dilution 1:40, CD68 (Klone PG-M, Dako) 
in dilution 1:50, according to the manufacturer’s instruc-
tions. Visualization of reaction products was performed 
using AEC (3-amino-9-ethyl-carbazole) as a chromogen 
(AEC Substrate Chromogen ready-to-use, DAKO, 
Denmark) for 10 minutes at room temperature. Sections 
were counterstained with hematoxylin and mounted in 
glycergel. For all antibodies a tonsil specimen was taken 
as the positive control. All stainings were performed with 
the same procedure but with the omission of the primary 
antibody as a negative control. 
RCAS1 expression was evaluated in an entire slide, in 
the glandular epithelium and the stromal cells, as follows: 
0 – no reactivity; +1 – weak, when any cytoplasmic stain-
ing pattern  (also granular in perinuclear region) was 
observed (in up to 10% of positive cells); +2 – marked 
cytoplasmic (sometimes together with membranous) 
staining in 11–30% of the cells); +3 – high expression 
(more than 30% of positive cells). 
The immune cells were calculated in an entire speci-
men, and an average cell number per 1hpf (high power 
field, objective magnification x40) was calculated. Vari-
able scales were used to evaluate semiquantitatively the 
number of cells, depending on their general number in 
the specimen. So, CD25+, CD56+ and CD69+ cells being 
very scarce were estimated as follows: 0 – lack of posi-
tive cells; +1 – single positive cells in the specimen; +2 
– 1–5 positive cells per 1hpf ; +3 – more than 5 positive 
cells/1hpf. For more abundant CD68+ and CD16+ cells 
the other scale was used: 0 – lack of positive cells; 1+ 
– 1–5 positive cells per 1hpf, 2+ – 6–10 cells/1hpf; 3+ 
– 11–20 positive cells /1hpf; 4+ – more than 20 positive 
cells per 1hpf. 
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 Statistical analysis
The distribution of variables in the examined groups 
of women checked with the use of the Shapiro-Wilk test 
showed that all of them were different from normal. 
Therefore, non-parametric testing was employed. Statis-
tical significance between the groups was determined by 
the Kruskal-Wallis analysis of variance (ANOVA) test. 
The Mann-Whitney U test was then used as applicable. 
The Spearman rank test was used to evaluate interclass 
correlation coefficients. All calculations were carried 
out with the use of STATISTICA software v. 6 (StatSoft, 
USA, 2001).
Results
Analysis of RCAS1 immunoreactivity
RCAS1 immunopositivity was revealed in 67% of 
endometrial tissue samples. RCAS1 positivity was visible 
in the endometrial epithelium without positive reaction 
in the proper stromal cells (Figure 1, Table 1).
A significantly lower RCAS1 expression in the 
endometrium was identified during the proliferative 
menstrual cycle phase than during the periovulatory 
one (p<0.01) and than during the secretory cycle phase 
(p<0.01). RCAS1 expression was at comparable levels 
during the secretory and the periovulatory cycle phases.
Figure 1. RCAS1 expression in: proliferative (A), periovulatory (B), and secretory (C,D) endometrium.
A - Weak positive glandular reaction in proliferative endometrium (horizontal arrow). Obj. magn. x20;
B - Strong immunoreactivity in glandular epithelium of periovulatory endometrium (horizontal arrows). Obj. magn. x20.
C - Strong immunoreactivity in glandular epithelium of secretory endometrium (horizontal arrows). Obj. magn. x20;
D - Strong immunoreactivity in glandular epithelium of secretory endometrium (horizontal arrows). Obj. magn. x60.
Table 1. RCAS1 expression in the endometrium referring to menstrual cycle changes.
Groups
RCAS1 Immunoreactivity
0 +1 +2 +3
Proliferative phase (n=8) 87 (7) 13 (1) - -
Periovulatory phase (n=10) 10 (1) 50 (5) 40 (4) -
Secretory phase (n=15) 20 (3) 60 (9) 20 (3) -
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 Analysis of immune cells presence and their activity
A significantly higher CD69 expression was identified 
in the periovulatory phase in comparison to the prolifera-
tive one (p=0.02), while CD69 expression was at a com-
parable level during the periovulatory and the secretory 
cycle phases. CD25 antigen expression was at a compa-
rable level in the proliferative and periovulatory phases, 
while during the secretory phase it was significantly lower 
than in the proliferative one (p<0.001), being also lower 
than in the periovulatory phase (p=0.056). The number 
of CD56 positive cells was highest during the secretory 
cycle phase, significantly higher than during the prolif-
erative and the periovulatory phases (p=0.01 and p=0.02, 
respectively). However, the number of CD56 positive 
cells was at a comparable level during the periovulatory 
and proliferative phases. No significant differences in the 
number of macrophages (CD68 immunoreactivity) and 
CD16 antigen expression were observed with respect to 
the menstrual cycle phases. (Table 2).
Discussion
A statistically significantly higher RCAS1 expression 
was observed in the periovulatory and the secretory 
menstrual cycle phases than in the proliferative phase. 
The immune system of the female reproductive tract is 
unique and is restricted by hormonal changes. The NK 
cells population present in the endometrium is repre-
sented mainly by CD56+CD16- cells [18,33]. The highest 
number of CD56 positive cells was found in our study in 
the secretory cycle phase and no CD16 antigen expression 
increase was disclosed with respect to hormonal changes 
during the menstrual cycle phases. Macrophages repre-
sent about 15% of endometrial cells and their number 
does not alter with respect to the menstrual cycle phases 
[7,18]. In our study CD16 and CD68 antigens expres-
sion did not alter. Additionally, a correlation between 
CD16 and CD68 expressions during the secretory and 
the periovulatory phases was found (R=0.73, p=0.001). 
Hormonal changes during the menstrual cycle are 
accompanied also by the alterations of the immune cell 
activity changes. Although CD25 and CD69 antigens are 
not highly specific (CD25 expression in the endometrium 
may result from the presence of CD4+CD25+ regulatory 
T (treg) cell suppressing the immune cells response [14]; 
CD69 is an antigen related to increase of activity of vari-
ous immune cells), the expression of activation markers 
in the endometrium (CD69, CD25, CD71, HLA-DR) 
seems to be closely associated with the NK cells popula-
tion [15]. The intensity of CD69 antigen expression was 
highest during the proliferative phase and decreased 
gradually through the menstrual cycle [22,42]. In our 
previous report a significantly higher CD69 antigen 
expression was observed during the secretory cycle phase 
when compared to the proliferative one, but without con-
sidering the periovulatory phase. In the present study we 
considered three cycle phases, including the secretory, 
the proliferative and  the periovulatory ones, and the 
highest level was found during the periovulatory cycle 
phase. CD69 antigen expression has to be discriminated 
from CD25 antigen expression on the same decidual 
lymphocytes [4]. CD56 positive cells within the endo-
metrium possess IL-2alfa receptor (CD25) and remain 
rather activated than in a resting state [33]. In our study 
CD25 was statistically significantly lower in the secre-
tory than in the proliferative cycle phase. This finding is 
Table 2. Immune cells number and their activity regarding to menstrual cycle changes.
Menstrual cycle phase Antigen
Intensity of staining
percentage (number of cases)
0 +1 +2 +3 +4
Proliferative (n=8) CD56 37.5 (3) 37.5 (3) 25 (2) - -
CD16 - 25 (2) 62 (5) 13 (1) -
CD68 - 13 (1) 87 (7) - -
CD25 - 38 (3) 62 (5) - -
Periovulatory (n=10)
CD69 87 (7) - 13 (1) - -
CD56 40 (4) 20 (2) 40 (4) - -
CD16 - - 90 (9) 10 (1) -
CD68 - - 80 (8) 20 (2) -
CD25 30 (3) 30 (3) 40 (4) - -
Secretory cycle (n=15)
CD69 30 (3) 20 (2) 40 (4) 10 (1) -
CD56 7 (1) 14 (2) 65 (10) 14 (2) -
CD16 - 14 (2) 47 (7) 32 (5) 7 (1)
CD68 - 28 (4) 65 (10) 7 (1) -
CD25 53 (8) 47 (7) - - -
CD69 65 (10) 14 (2) 21 (3) - -
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in agreement with the data published by Ho et al., who 
disclosed a higher CD25 expression in the proliferative 
than in the secretory phase [15]. Down-regulation of IL-2 
receptor expression in decidual lymphocytes is observed 
despite the evidence of lymphocyte activation [4]. Thus, 
an increase of CD69 expression during the periovula-
tory phase in comparison to the proliferative one with a 
concomitant lower CD25 expression might result from a 
selective CD25 suppression [4]. A similar phenomenon 
was reported on the lymphocytes in human cervical 
cancer [36]. The host immune tolerance in neoplasms 
seems to be similar to the maternal immune tolerance 
during pregnancy [6]. According to Chao the differences 
in immune markers expression might result from certain 
inhibitory mediators derived from the feto-placental unit 
or other decidual components [4]. RCAS1 expression 
increases gradually with menstrual cycle changes in the 
endometrium. The role of this protein in the creation of 
the maternal immune tolerance during pregnancy has 
been  reported recently. RCAS1 expression was identi-
fied within the trophoblast and the placenta [29,47]. This 
protein might be a factor responsible for this selective 
suppression quoted above.
A gradual increase of RCAS1 expression within 
the endometrium during the periovulatory and the 
secretory phases might be secondary to the increasing 
cytotoxic activity during the menstrual cycle phases until 
it reaches the level necessary fort the ovum implantation. 
Differences in the expression of some cytotoxic activity 
markers (CD25, CD69) might probably result from 
differences in the expression of factors responsible for 
selective inhibition of cytotoxic cells. i.e. RCAS1. Endo-
metrial cells modulate local activity of immune cells by 
their activation and inhibition. A higher IL-15 secretion 
was reported during the secretory cycle phase. This 
cytokine is crucial for NK cells proliferation and survival 
[19]. The growing increase of IL-13 simultaneous with 
IL-15 (which is responsible for the inhibition of Th1 
cytokines production) [32]. Decidualization begins in 
every ovulation in which the immune system combined 
with the endometrium reaches proper activity enabling 
implantation and preventing abortion. CD69 and CD25 
expression on lymphocytes was also demonstrated in 
the decidua during spontaneous abortion [31,15]. On 
the other hand, a high amount of NK cells and high 
pre-conceptional NK cells activity are associated with 
an increased pregnancy loss [35,49]. Alterations in 
cytotoxic cells number and the activity in the endome-
trium are associated with the endometrial reproductive 
function. The aim of such a phenomenon is to cumulate 
the adequate number of activated cytotoxic cells within 
the endometrium. The balance between the increasing 
intensity of the immune response and endometrial cells, 
independently of the presence or lack of ovum implan-
tation, seems to be maintained by the expression on 
endometrial cells factors or their secretion affecting the 
immune cells activity to the extracellular matrix. These 
factors include Fas-L, DcR3, IL-11, of a well-known role 
in this process, but also RCAS1 [12,23,50].
In conclusion, RCAS1 endometrial expression may 
favor the coexistence of active lymphocytes and endo-
metrial cells.
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